---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024980"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:47:54.317215+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eledon reports Q3 net loss $10.5M; advances tegoprubart with FDA IND clearances

## Summary
- Net loss of $10.5M ($0.73/share) vs $9.8M ($0.66/share) in Q3 2021.
- Cash and equivalents $65.9M as of Sep 30, 2022; runway into 2024.
- FDA cleared IND for Phase 2 trial of tegoprubart in kidney transplant prevention.
- FDA cleared IND for tegoprubart in IgA Nephropathy; global Phase 2a enrolling.
- Initial data from kidney, islet cell, and IgAN studies expected Q1 2023.

## SEC filing metadata
- accession: 0000950170-22-024980
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017022024980/0000950170-22-024980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017022024980/eldn-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024980
- JSON: https://secwatch.observer/filing/0000950170-22-024980.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024980.txt

## Key facts
- Earnings Releases
  Eledon Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: net income $10.5 million, EPS $0.73 per share.
  - Period: the three months ended September 30, 2022
  - Net income: $10.5 million
  - EPS: $0.73 per share
  - Result: reported results
  source text: The company reported a net loss of $10.5 million, or $0.73 per share, for the three months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404281/000095017022024980/0000950170-22-024980-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.